Biotech Values

[DewDiligence]

From the same WP editorial:

Of the 12 new cancer drugs approved by the Food and Drug Administration last year, 11 were priced above $100,000 annually.

Adding in Kadcyla, whose US price is well above $100K per year, that makes 12 out of 13.